Volume 16, Issue 64 (1-2008)                   JGUMS 2008, 16(64): 60-66 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Doosti A, Davoodi N. Vaccination of C57BL/6 Mice with Transgenic Leishmania Major. JGUMS 2008; 16 (64) :60-66
URL: http://journal.gums.ac.ir/article-1-345-en.html
1- , doostiiranii@yahoo.com
Abstract:   (6283 Views)
Abstract Introduction: Leishmania is a kind of infection which arises of a mono cell. This disease prevalenced in topical countries of world. In despite of several studies which are done in overall the world, researchers didn’t find an effective vaccination for it and common treatments didn’t effective completely. Infect to leishmania create permanent immunity. Thus vaccination is the only cost-effective means to control leishmania. Objective: Assaying the obtained immunogenecity by vaccination of C57BL/6 mice with transgenic leishmania major. Materials and Methods: In present study transgenic strain of L. major which express two suicide genes thymidine kinase gene of Herpes Simplex Virus type 1(HSV-tk) and cytosine deaminase gene of Saccharomyces cervisiea (Sc-cd) in its genome have been used for vaccination of mice. C57BL/6 mice were infected by transgenic L. major and treated with ganciclovir and 5-fluorocytosine together. Result: The ELISA cytokine assay in this group showed high increase of IFN- γ and low IL-4, next challenge in vaccination was blocked disease progression, which was due to high level of immunity. Conclusion: The inducible expression of suicide gene and drug can used as valuable method to find the safe and effective vaccine against Leishmaniasis.
Full-Text [PDF 204 kb]   (1689 Downloads)    
Review Paper: Research | Subject: Special
Received: 2013/12/24 | Accepted: 2013/12/24 | Published: 2013/12/24

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb